圣地亚哥 - 市值7.96亿美元的生命科学试剂和服务供应商Maravai LifeSciences, Inc. (NASDAQ: MRVI)宣布收购Molecular Assemblies, Inc.的知识产权和资产。根据 InvestingPro 数据，该公司保持强劲的流动性，流动比率为10.74，尽管面临近期挑战，过去十二个月收入下降34%。此次收购将增强Maravai子公司TriLink ...

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has partnered with, ...

北京时间2025年01月18日03时33分，Maravai Lifesciences Holdings, Inc.（MRVI.us）股票出现异动，股价急速上涨5.03%。截至发稿，该股报4.80 ...

EST Maravai Lifesciences (MRVI) jumps 6% to $5.85 after MAI IP acquisition announcementInvest with Confidence: Follow TipRanks' Top Wall ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the target of some unusual options trading on ...

General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of ...

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual ...

TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases.